6-methoxy-3-[(4-[1,2,3]triazol-1-ylmethyl-naphthalene-1-carbonyl)-amino]-pyridine-2-carboxylic acid cyclohexylmethyl-amide

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 6-methoxy-3-[(4-[1,2,3]triazol-1-ylmethyl-naphthalene-1-carbonyl)-amino]-pyridine-2-carboxylic acid cyclohexylmethyl-amide
• 英文别名: N-(cyclohexylmethyl)-6-methoxy-3-{[4-(1H-1,2,3-triazol-1-ylmethyl)-1-naphthoyl]amino}pyridine-2-carboxamide；N-(cyclohexylmethyl)-6-methoxy-3-[[4-(triazol-1-ylmethyl)naphthalene-1-carbonyl]amino]pyridine-2-carboxamide
• 化学式: C₂₈H₃₀N₆O₃
• 分子量: 498.585
• InChiKey: LYYMDSUUZZBFPN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.1
• 重原子数：
  37
• 可旋转键数：
  8
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  111
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  6-methoxy-3-[(4-[1,2,3]triazol-1-ylmethyl-naphthalene-1-carbonyl)-amino]-pyridine-2-carboxylic acid cyclohexylmethyl-amide 在 吡啶盐酸盐 作用下， 反应 0.42h， 以69%的产率得到6-hydroxy-3-[(4-[1,2,3]triazol-1-ylmethyl-naphthalene-1-carbonyl)-amino]-pyridine-2-carboxylic acid cyclohexylmethyl-amide
  参考文献：
  名称：

  [EN] THERAPEUTIC COMPOUNDS: PYRIDINE AS SCAFFOLD
  [FR] COMPOSES THERAPEUTIQUES DANS LESQUELS LA PYRIDINE EST UTILISEE COMME SQUELETTE

  摘要：

  其中A、A1、A2、A3、A4、R2、R3、R4和n的化合物的公式I、IA和IB或IC或其药学上可接受的盐：其中A、A1、A2、A3、A4、R2、R3、R4和n的定义如规范中所述，以及包括这些化合物的盐和药物组合物已经准备好。它们在治疗中很有用，特别是在疼痛管理中。

  公开号：

  WO2005115986A1
• 作为产物：
  描述：

  4-甲基-1-萘甲酰氯 在 N-溴代丁二酰亚胺(NBS) 、 N,N-二异丙基乙胺 、 过氧化苯甲酰 作用下， 以 四氯化碳 、 DMF (N,N-dimethyl-formamide) 为溶剂， 反应 4.17h， 生成 6-methoxy-3-[(4-[1,2,3]triazol-1-ylmethyl-naphthalene-1-carbonyl)-amino]-pyridine-2-carboxylic acid cyclohexylmethyl-amide
  参考文献：
  名称：

  [EN] THERAPEUTIC COMPOUNDS: PYRIDINE AS SCAFFOLD
  [FR] COMPOSES THERAPEUTIQUES DANS LESQUELS LA PYRIDINE EST UTILISEE COMME SQUELETTE

  摘要：

  其中A、A1、A2、A3、A4、R2、R3、R4和n的化合物的公式I、IA和IB或IC或其药学上可接受的盐：其中A、A1、A2、A3、A4、R2、R3、R4和n的定义如规范中所述，以及包括这些化合物的盐和药物组合物已经准备好。它们在治疗中很有用，特别是在疼痛管理中。

  公开号：

  WO2005115986A1

文献信息

• Therapeutic Compounds: Pyridine as Scaffold
  申请人：Amin Kosrat

  公开号：US20070225292A1

  公开（公告）日：2007-09-27

  Compounds of formula I or pharmaceutically acceptable salts thereof: wherein R 1 , R 2 , R 3 , R 4 , n and A are as defined in the specification as well as salts and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain.

  式I的化合物或其药学上可接受的盐：其中R1，R2，R3，R4，n和A的定义如规范中所述，以及包括该化合物的盐和制备的药物组合物。它们在治疗中有用，特别是在疼痛管理方面。
• Novel 3-Bicyclocarbonylaminopyridine-2-Carboxamides or 3-Bicyclocarbonylaminopyrazine-2-Carboxamides
  申请人：Amin Kosrat

  公开号：US20090181968A1

  公开（公告）日：2009-07-16

  The present invention relates to compounds of formula (I) [Chemical formula should be inserted here. Please see paper copy] as well as pharmaceutically acceptable salts and pharmaceutical compositions including the compounds are prepared or thereof: wherein, A 1 , A 2 , R 1 , R 2 , R 3 , R 4 , and R 5 and n are as defined in the specification. The compounds of formula (I) are useful in therapy.

  本发明涉及公式（I）的化合物[化学式应在此处插入。请参阅纸质副本]以及制备该化合物的药学上可接受的盐和制药组合物：其中，A1、A2、R1、R2、R3、R4、R5和n如规范所定义。公式（I）的化合物在治疗中有用。
• Discovery of Agonists of Cannabinoid Receptor 1 with Restricted Central Nervous System Penetration Aimed for Treatment of Gastroesophageal Reflux Disease
  作者：Alleyn T. Plowright、Karolina Nilsson、Madeleine Antonsson、Kosrat Amin、Johan Broddefalk、Jörgen Jensen、Anders Lehmann、Shujuan Jin、Stephane St-Onge、Mirosław J. Tomaszewski、Maxime Tremblay、Christopher Walpole、Zhongyong Wei、Hua Yang、Johan Ulander

  DOI：10.1021/jm301511h

  日期：2013.1.10

  Agonists of the cannabinoid receptor 1 (CB1) have been suggested as possible treatments for a range of medical disorders including gastroesophageal reflux disease (GERD). While centrally acting cannabinoid agonists are known to produce psychotropic effects, it has been suggested that the CB1 receptors in the periphery could play a significant role in reducing reflux. A moderately potent and highly lipophilic series of 2-aminobenzamides was identified through focused screening of GPCR libraries. Development of this series focused on improving potency and efficacy at the CB1 receptor, reducing lipophilicity and limiting the central nervous system (CNS) exposure while maintaining good oral absorption. Improvement of the series led to compounds having excellent potency at the CB1 receptor and high levels of agonism, good physical and pharmacokinetic properties, and low penetration into the CNS. A range of compounds demonstrated a dose-dependent inhibition of transient lower esophageal sphincter relaxations in a dog model.
• THERAPEUTIC COMPOUNDS: PYRIDINE AS SCAFFOLD
  申请人：AstraZeneca AB

  公开号：EP1756060A1

  公开（公告）日：2007-02-28
• NEW COMPOUNDS
  申请人：AstraZeneca AB

  公开号：EP1957478A2

  公开（公告）日：2008-08-20